### Learner Notification

**MED Learning Group**

**Focusing on Patient Perspectives for Optimal Management of Moderate-to-Severe Atopic Dermatitis**

**November 20, 2023 – November 20, 2024**

**Online**

**Acknowledgement of Financial Commercial Support**

Sanofi and Regeneron Pharmaceuticals, Inc.

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 0.50 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Identify patient-specific strategies to assess and improve the quality of life for patients with moderate to severe AD.
2. Describe the efficacy and safety of systemic therapies for AD to aid in the selection of treatments for patients with moderate-to-severe disease.
3. Integrate the clinical evidence.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Russie | Allen | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Deb | Gordon | NA |
| Alexis | Klinger | NA |
| Peter | Lio | AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, MyOR Diagnostics, ParentMD, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme: Speakers Bureau, Alphyn Biologics, AbbVie, Almirall, Amyris, ASLAN, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant, Eli Lilly, Galderma, Janssen, Johnson & Johnson, Kimberly-Clark, LEO Pharma, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Sonica, Theraplex, UCB, Unilever, Verrica, Yobee Care: Advisory Board, AbbVie, AOBiome: Research, Theraplex: Patent Holder, Codex Labs, Concerto Biosci, Yobee Care: Stock Shareholder |
| Marissa | Mays-Verman | NA |
| Amy | Paller | AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, UCB: Investigator, Aegerion Pharmaceuticals, Azitra, BioCryst, Boehringer-Ingelheim, Bristol-Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy Dermatology, TWI Biotechnology, UCB: Consultant, AbbVie, Abeona Therapeutics, Catawba Research, Galderma, InMed: Data and Safety Monitoring Board |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email Certificate@AmedcoEmail.com